Last updated: July 27, 2026
Gadavist (gadobutrol) is a macrocyclic gadolinium-based contrast agent (GBCA) used for MRI. Public clinical activity is limited relative to label expansion, with the market driven by MRI volumes, hospital purchasing patterns, and GBCA safety and reimbursement dynamics. Near-term revenue exposure is primarily substitution risk from other GBCA brands and generic or biosimilar-like competitive pressure depending on country-level availability.
What is the current clinical trial landscape for Gadavist (gadobutrol)?
Clinical trials for gadobutrol are not concentrated in late-stage Phase 3 programs as of the latest generally visible public record. Most visible activity is typically incremental (registry studies, observational safety work, dosing/usage evaluations, or country-specific studies), while core efficacy is supported by earlier dossiers and established clinical practice.
What trial types are most common for gadobutrol around MRI contrast use?
- Observational post-marketing safety studies (renal safety, adverse event characterization, contrast reaction monitoring).
- Imaging performance studies that compare contrast enhancement in specific anatomical workflows.
- Protocol optimization studies (dose adjustments within label range, injection workflows).
- Country-specific bridging studies for local regulatory submissions and market access.
How do trial pipelines for GBCA competitors affect Gadavist’s future label and uptake?
Competitor pipelines for GBCAs tend to focus on:
- Comparative performance claims (image quality, lesion detectability).
- Safety evidence under different risk strata (renal impairment, pediatric use).
- Administration convenience endpoints (injector compatibility, workflow time).
These patterns shape hospital formulary behavior more than incremental clinical endpoints, because GBCA switching is often procurement-led.
How does Gadavist perform in market access and MRI utilization across major geographies?
Gadavist’s addressable market tracks MRI throughput and inpatient outpatient mix, with additional pull from oncology imaging, neurology imaging, and musculoskeletal indications where contrast enhancement improves lesion characterization.
What indications drive GBCA demand most?
Across GBCA classes, incremental GBCA utilization is most strongly linked to:
- Central nervous system imaging (tumor, demyelination, vascular lesions).
- Oncology lesion characterization and staging follow-up.
- Musculoskeletal imaging and inflammatory disease evaluation.
- Body imaging workflows where contrast-enhanced MRI alternatives compete with CT and ultrasound.
What procurement factors determine Gadavist share?
Hospital purchasing typically weighs:
- Price per dose and rebate structures.
- Tendering and long-term supply agreements.
- Formulary preferences for macrocyclic stability and perceived safety profiles.
- Availability of pack sizes and device compatibility.
- Local regulatory and pharmacovigilance experience.
What does the competitive landscape look like for Gadavist versus other GBCAs?
Gadavist competes against other branded GBCA products and, where approved, cheaper local offerings. Market share is usually determined by procurement contracts rather than by brand-level clinical differentiation at the point of purchase.
How does gadobutrol compare with macrocyclic and linear GBCA competitors?
- Gadavist (gadobutrol) is macrocyclic, aligning with market preference trends toward macrocyclic agents.
- Competitors with similar macrocyclic profiles can displace Gadavist if pricing and tender wins favor them.
- Linear GBCA penetration depends on country-specific guidance and payer policies that may shift demand toward macrocyclic agents.
What substitution risks exist for Gadavist?
Substitution risk rises when:
- Competitors offer materially lower acquisition cost per mL or per millimole.
- Tender cycles repeat with new bidding.
- Hospital groups consolidate GBCA contracts across sites.
- Payors push toward cost-effective MRI pathways, including contrast alternative sourcing.
When does Gadavist lose exclusivity, and what does that mean for generic entry risk?
Gadavist exclusivity depends on jurisdiction and patent portfolio structure, which vary by country and dosage presentation. In practice, the most relevant market-impacting events are patent expirations on:
- Active ingredient composition and related chemical matter
- Formulation, concentration, and container-specific claims
- Manufacturing processes
- Method-of-use or imaging protocol claims
What to monitor for generic and follow-on product entry risk
- Orange Book status for the US (if applicable listings exist for gadobutrol products).
- First generic or “follow-on” product approvals in each market.
- Patent settlement announcements tied to Paragraph IV challenges in the US (if present in the gadobutrol filing record).
- Tender-level switching after first lower-priced procurement award.
(No complete, verifiable Orange Book / patent-expiration dataset is provided in the prompt. Without that, a reliable exclusivity timeline cannot be stated.)
What is the Orange Book status of Gadavist (gadobutrol)?
No Orange Book dataset is included in the input provided, and a complete Orange Book status statement cannot be generated accurately without a verified listing table. A correct “Orange Book status of Gadavist” requires product-specific NDA/BLA identifiers, listing type, and patent expiration dates.
What patent estate protects gadobutrol products like Gadavist, and how strong is it?
A defensible patent-estate strength assessment requires enumerated, jurisdiction-linked patents (composition, formulation, method-of-use, manufacturing), with verified claim scope and remaining term. The prompt does not provide such a patent list.
What claim clusters typically matter for GBCA market exclusivity
- Macrocyclic gadolinium chelate composition claims.
- Crystallinity/polymorph or salt form.
- Concentration and formulation claims (including stabilization excipients).
- Container closure system claims (less common but relevant in some cases).
- Manufacturing process claims (residual metal control, purity specifications).
- Imaging protocol claims (dose, timing, sequence use), usually weaker when broadly practiced.
A market projection should therefore not hinge on generic “patent strength” without a verified patent table.
What FDA regulatory pathway does Gadavist use, and what approvals matter commercially?
Gadovist is an FDA-approved GBCA. Commercial significance typically comes from:
- Label expansions that broaden authorized use.
- Pediatric population additions (when granted).
- Any restriction changes related to renal safety messaging.
- Product line expansions (pack size, concentration offerings).
What regulatory events can shift demand
- Changes to dosing guidance or warnings that affect physician ordering patterns.
- Added patient risk stratification that increases screening workflow.
- Safety communications that drive switching within GBCA classes.
(No FDA label revision log, PLR, or supplement timeline is provided in the prompt.)
How do dosing, formulation, and concentration characteristics influence uptake for Gadavist?
Gadovist’s uptake is shaped by:
- Concentration per mL and total deliverable dose.
- Injector system compatibility and workflow simplicity.
- Stability and shelf-life that affect hospital logistics.
- Pack size and procurement economies.
What formulation attributes can create price leverage
Hospitals prefer the lowest cost that maintains:
- Consistent dosing accuracy (mL-to-dose conversion).
- Reliable injection volume and imaging timing.
- Reduced wastage in high-throughput MRI suites.
This can favor one competitor if their concentration and vial sizing reduces waste even at higher list price.
What clinical outcomes and safety evidence influence payer and hospital decisions for gadobutrol?
Safety messaging and clinical effectiveness typically converge in procurement rules:
- Macrocyclic stability and perceived lower dechelation risk supports macrocyclic preference trends.
- Renal impairment screening workflows affect contrast ordering behavior.
- Adverse event rates influence protocol compliance and formulary committees.
What endpoints matter most for GBCA comparative adoption
- Incidence of adverse drug reactions.
- Renal impairment-related safety outcomes.
- Image quality endpoints that correlate with lesion detectability and diagnostic confidence in routine workflows.
Market analysis: TAM, drivers, and demand outlook for Gadavist (2026–2036)
Demand drivers
- Global MRI utilization growth driven by outpatient migration and oncology surveillance.
- Increasing CNS oncology burden and follow-up imaging intensity.
- Expansion of MRI capacity in emerging markets.
- Contracting and tender behavior favoring macrocyclic agents.
Downside drivers
- GBCA cost pressure from hospital system consolidation and tender renegotiations.
- Competitive price compression from other branded macrocyclic agents and lower-priced alternatives.
- Regulatory or payer changes affecting MRI contrast utilization rates in at-risk populations.
What shapes commercial outcomes at the company level
- Ability to secure multi-site supply agreements.
- Portfolio breadth (multiple concentrations/pack sizes to match workflows).
- Pharmacovigilance and risk communication execution supporting “switch stability.”
Revenue projection for Gadavist: scenario-based outlook (2026–2036)
A quantified revenue forecast requires a baseline revenue series, geography-level pricing, volume data, and competitive share trends. The prompt does not provide Gadavist revenue, unit share, or any dataset to anchor a numerical forecast.
Therefore, a complete, accurate revenue projection cannot be produced from the supplied information.
What generic launch scenarios could affect Gadavist in specific markets?
Without a verified patent and regulatory status table, it is not possible to specify:
- Which filings would be first eligible for approval.
- Expected launch dates by jurisdiction.
- Likely settlement terms or “at-risk” launch risk windows.
- Competitive displacement timing relative to tender cycles.
How does Gadavist compare with the overall GBCA market in pricing and growth?
GBCAs typically grow with MRI volumes, with price influenced by contracting and tender dynamics. Macrocyclic positioning can support pricing relative to less preferred alternatives, but price discipline is common once multiple macrocyclic options are available in a hospital group.
What to measure to track Gadavist share
- Unit market share by dose and by pack size.
- Net price after rebates and tender adjustments (not list).
- Hospital group penetration (accounts, sites, and contract durations).
- Switching velocity after competitor tender wins.
Key Takeaways
- Gadavist clinical activity appears incremental rather than driven by major late-stage Phase 3 label expansions in the publicly visible record.
- Market demand tracks MRI utilization and imaging intensity in oncology, neurology, and musculoskeletal workflows.
- Procurement and tender economics are the primary determinants of brand share, with macrocyclic preference supporting baseline positioning.
- A reliable exclusivity, Orange Book status, patent-expiration timeline, and quantified revenue projection cannot be produced from the information provided in the prompt.
FAQs
- What clinical evidence supports gadobutrol image quality in MRI oncology workflows?
- How do renal safety communications change GBCA ordering patterns in hospital radiology departments?
- What tender and rebate structures most affect GBCA brand net price outcomes?
- What country-level regulatory timelines most influence GBCA switching after patent events?
- How can vial concentration and injection-volume compatibility shift GBCA procurement decisions?
References
(No sources were provided in the prompt, and no in-scope dataset is included to support citation-backed claims.)
